Choose a folder
DISCOVER investigators assemble at ADA 2017
Investigators and Scientific Committee members held rewarding meetings at the 77th Scientific Sessions of the American Diabetes Association to catch up on all the latest developments, share their experiences and plan for the future of DISCOVER.
The DISCOVER investigator meeting, held on Sunday 11 June, was attended by 30 investigators from all over the world, as well as representatives from local AstraZeneca teams. The Scientific Committee was pleased to discuss the progress of the study, share some of the baseline data, and outline the publications plan and patient retention strategies. Above is a video featuring Dr Dhiãnah Santini de Oliveira Chachamovitz, an investigator from Brazil, who commented on the variation in treatment patterns across DISCOVER countries:
“DISCOVER is my first real world evidence study and I have realized that the treatment of diabetes is sometimes not a question of choice but a question of chance.”
Two posters and an oral presentation featured at ADA 2017, describing selection of glucose-lowering medication, glycaemic control and vascular complications in patients with type 2 diabetes initiating second-line treatment. More information about these presentations can be found on the DISCOVER website.
The DISCOVER Scientific Committee also held a very productive meeting on Saturday 10 June at ADA 2017 to continue their work organizing the study and its publications as year 1 data collection is nearing completion.
Thank you to everyone working on DISCOVER! The progress of this ambitious study would not be possible without your sustained efforts to collect comprehensive and accurate data.
For future updates, please keep visiting the DISCOVER website.